IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
WOEST ( What is the Optimal antiplatElet & Anticoagulant Therapy in Patients With Oral Anticoagulation and Coronary StenTing) (WOEST)
This study has been completed.
Sponsor:
R&D Cardiologie
Information provided by (Responsible Party):
W. Dewilde, R&D Cardiologie
ClinicalTrials.gov Identifier:
NCT00769938
First received: October 8, 2008
Last updated: January 12, 2013
Last verified: January 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The study will assess the hypothesis that the combination warfarin & clopidogrel 75 mg/day is superior to triple therapy (warfarin + clopidogrel 75mg/day + aspirin 80mg/day) with respect to bleeding complications while equally safe with respect to the prevention of thrombotic complications in patients with both indications for warfarin use and dual antiplatelet (clopidogrel 75mg/day + aspirin 80mg/day) treatment.
| Condition | Intervention | Phase |
|---|---|---|
| Anticoagulants Platelet Aggregation Inhibitors Stents Atrial Fibrillation | Device: PCI (percutaneous coronary intervention) | Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | What is the Optimal antiplatElet & Anticoagulant Therapy in Patients With Oral Anticoagulation and Coronary StenTing |
Resource links provided by NLM:
Genetics Home Reference related topics:
familial atrial fibrillation
MedlinePlus related topics:
Blood Thinners
U.S. FDA Resources
Further study details as provided by W. Dewilde, R&D Cardiologie:
Primary Outcome Measures:
- The combined end point of minor, moderate or major bleeding complications during the initial hospitalization & one year follow-up. (TIMI & GUSTO criteria). [ Time Frame: 1 year ]
Secondary Outcome Measures:
- The combined event of death, myocardial infarction, stroke, systemic embolization & target vessel revascularisation and the individual components of the composite primary and secondary endpoints. [ Time Frame: 1 year ]
| Enrollment: | 573 |
| Study Start Date: | December 2008 |
| Study Completion Date: | August 2012 |
| Primary Completion Date: | August 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: Aspirin + clopidogrel + oral anticoagulation |
Device: PCI (percutaneous coronary intervention)
only patients scheduled for PCI can be included tough this intervention would also take place without this study. What we want to study is the difference in outcome after a little change in the antithrombotic treatment
|
| Active Comparator: Oral anticoagulants + clopidogrel |
Device: PCI (percutaneous coronary intervention)
only patients scheduled for PCI can be included tough this intervention would also take place without this study. What we want to study is the difference in outcome after a little change in the antithrombotic treatment
|
Detailed Description:
Chronic oral antithrombotic treatment is necessary in patients with mechanical heart valves and in the majority of patients with atrial fibrillation. When these patients have to undergo Percutaneous Coronary Intervention (PCI) with stenting, there is also an indication for treatment with aspirin and clopidogrel. However, triple therapy is known to augment the risk for bleeding complications.Unfortunately, no prospective data are available to solve this issue. Nevertheless, it all comes down to finding the ideal therapy in patients with both atrial fibrillation and percutaneous intervention to prevent thrombotic complications (e.g. stent thrombosis) without increasing the risk of bleeding. This prospective randomised study will assess the hypothesis that in patients on warfarin therapy and indication for elective percutaneous intervention, the combination warfarin & clopidogrel 75 mg/day is superior to triple therapy treatment in reducing the risk of bleeds while equally safe with respect to the prevention of thrombotic complications
Eligibility| Ages Eligible for Study: | 18 Years to 80 Years (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Patients is on oral anticoagulation therapy and this will be continued throughout the period of 1 year-and deployment of at least 1 coronary stent (bare metal stent (BMS) or drug eluting stent (DES)). -age of more than 18 years
Exclusion Criteria:
- cardiogenic shock,
- contra-indication for aspirin or clopidogrel
- allergy to aspirin or clopidogrel,
- documented peptic ulcer disease within the previous six months,
- pregnancy and
- previous intracerebral haemorrhage or
- significant thrombocytopenia (platelet count < 50x10 9/L).
- major bleeding according to timi criteria within the past 12 months
- age > 80 years
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00769938
Please refer to this study by its ClinicalTrials.gov identifier: NCT00769938
Locations
| Belgium | |
| OLV Aalst | |
| Aalst, Belgium | |
| UZ Antwerpen | |
| Antwerpen, Belgium | |
| ZOL | |
| Genk, Belgium | |
| Maria Middelares | |
| Gent, Belgium | |
| UZ KU Leuven | |
| Leuven, Belgium | |
| Netherlands | |
| MCA Alkmaar | |
| ALkmaar, Netherlands | |
| Academisch Medisch Centrum Amsterdam | |
| Amsterdam, Netherlands | |
| OLVG | |
| Amsterdam, Netherlands | |
| Amphia Ziekenhuis | |
| Breda, Netherlands | |
| Catharina Ziekenhuis | |
| Eindhoven, Netherlands | |
| UMCG | |
| Groningen, Netherlands | |
| Sint Antonius Ziekenhuis | |
| Nieuwegein, Netherlands, 3435 CM | |
| Zuiderziekenhuis | |
| Rotterdam, Netherlands | |
| Twee Steden Ziekenhuis | |
| Tlibrug, Netherlands | |
| Isala klinieken | |
| Zwolle, Netherlands | |
Sponsors and Collaborators
R&D Cardiologie
More Information
Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | W. Dewilde, Dr, R&D Cardiologie |
| ClinicalTrials.gov Identifier: | NCT00769938 History of Changes |
| Other Study ID Numbers: |
RDC-2008-03 |
| Study First Received: | October 8, 2008 |
| Last Updated: | January 12, 2013 |
Keywords provided by W. Dewilde, R&D Cardiologie:
|
Atrial fibrillation Percutaneous coronary stenting Bleeding complications Triple therapy |
Additional relevant MeSH terms:
|
Atrial Fibrillation Arrhythmias, Cardiac Heart Diseases Cardiovascular Diseases Pathologic Processes Clopidogrel Anticoagulants Platelet Aggregation Inhibitors |
Purinergic P2Y Receptor Antagonists Purinergic P2 Receptor Antagonists Purinergic Antagonists Purinergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on July 28, 2017